| 2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome |
Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390. |
 |
| 2023-11 |
The registry of genetic alterations of Taiwan NSCLC by comprehensive next-generation sequencing: A real-world cohort study - TCOG T1521 study |
Journal of Thoracic Oncology. 2023 Nov;18(11, Suppl.):S52. |
|
| 2022-11 |
BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma |
Annals of Oncology. 2022 Nov;33(Suppl. 9):S1472-S1473. |
|
| 2022-07 |
A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S478. |
|
| 2021-09 |
A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer |
Annals of Oncology. 2021 Sep;32(Suppl. 5):S377. |
|
| 2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma |
Journal of Clinical Oncology. 2021 May;39(15, Suppl.):4143. |
|
| 2021-05 |
A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy |
Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 6025. |
|
| 2019-05 |
An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14) |
Journal of Clinical Oncology. 2019 May;37(15, Suppl. S):Abstract number 4101. |
|
| 2017-05 |
Efficient group-sequential designs for monitoring two time-to-event outcomes in clinical trials |
Trials. 2017 May;18(Suppl. 1):Meeting Abstract P36. |
|
| 2016-11-11 |
Assessing benefit and consistency of treatment effect under a discrete random effects model in multiregional clinical trials |
Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. 2016 Nov 11:127-136. |
|
| 2016-10 |
The role of pre-treatment plasma Epstein-Barr virus (EBV) DNA as a predictive biomarker of induction chemotherapy for stage IVA or IVB nasopharyngeal carcinoma (NPC) patients - A Subgroup Analysis on Taiwan Cooperative Oncology Group (TCOG) 1303 study |
Annals of Oncology. 2016 Oct;27(Suppl.6 ):Meeting Abstract 973P. |
|
| 2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial |
Journal of Gastroenterology and Hepatology. 2015 Dec;30(Suppl. S4):99. |
|
| 2015-05 |
Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4101. |
|
| 2015-05 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4024. |
|
| 2014-10 |
Use of a bayesian approach to design and evaluation of NCE2 |
Pharmacoepidemiology and Drug Safety. 2014 Oct;23(S1):432. |
|
| 2014-09 |
The effect of intervention with potassium and magnesium-enriched salt on neurological performance in stroke patients |
Cerebrovascular Diseases. 2014 Sep;38(Suppl. 1):98. |
|
| 2014-04 |
Prevention of chemotherapy-induced hbv-related hepatitis flare in lymphoma patients with resolved hbv infection: Cost analysis |
Journal of Hepatology. 2014 Apr;60(1):S206-S207. |
|
| 2013-09 |
Use of random effect models in the design and analysis of multi-regional clinical trials |
Topics in Applied Statistics. 2013 Sep;55:325-344. |
|
| 2013-05 |
Impact of virologic factors on recurrence-free survival in HBV-related hepatocellular carcinoma after surgical resection: Post hoc analysis from a prospective study with long-term follow-up |
Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number e15032. |
|
| 2011-05 |
Genetic polymorphisms in PXR associated with serum concentration and metabolism to treatment with the antidepressant paroxetine |
Drug Metabolism Reviews. 2011 May;43(Suppl.1):71. |
|
| 2011-05 |
The genetic polymorphisms in ALDH2 influence the methadone dose and adverse reactions in patients with heroin addiction |
Drug Metabolism Reviews. 2011 May;43(Suppl.1):26. |
|
| 2011-05 |
Opioid receptor Mu1 genetic polymorphisms influence QT prolongation and insomnia in methadone maintenance patients |
Biological Psychiatry. 2011 May;69(9 Suppl.1):229S-230S. |
|
| 2010-11 |
Medical resources utilization of five most prevalent cancers in Taiwan (lung cancer, liver cancer, colorectal cancer, gastric cancer, and brest cancer): 2001 similar to 2007 |
Value in Health. 2010 Nov;13(7):A279. |
|
| 2008-11 |
A population study on the age-specific relationship between body mass index, metabolic disorders, and utilization of ambulatory services |
Value in Health. 2008 Nov;11(6):A648. |
|
| 2008-02 |
Increased risk for entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan |
PLoS Neglected Tropical Diseases. 2008 Feb;2(2):Article number e175 |
|
